TY - GEN
T1 - Thymosin α1
T2 - A historical overview
AU - Garaci, Enrico
PY - 2007/9
Y1 - 2007/9
N2 - Thymosin α 1 (Tα1), initially isolated from thymus, was characterized by Allan Goldstein in 1977. Since the beginning, our studies were aimed at evaluating its immunomodulating effects when used in combination with cytokines and chemotherapy. Combination therapies have now proved to be effective in inhibiting tumoral growth and in controlling infective diseases especially in the immunocompromised host. More recent studies showed that Tα1 molecule increased major histocompatibility complex (MHC) class-1 and Toll-like receptor expression as well as cytokine production, suggesting its immunoregulatory role. Overall these results led us to start pilot clinical trials on patients with hepatitis C and cancer.
AB - Thymosin α 1 (Tα1), initially isolated from thymus, was characterized by Allan Goldstein in 1977. Since the beginning, our studies were aimed at evaluating its immunomodulating effects when used in combination with cytokines and chemotherapy. Combination therapies have now proved to be effective in inhibiting tumoral growth and in controlling infective diseases especially in the immunocompromised host. More recent studies showed that Tα1 molecule increased major histocompatibility complex (MHC) class-1 and Toll-like receptor expression as well as cytokine production, suggesting its immunoregulatory role. Overall these results led us to start pilot clinical trials on patients with hepatitis C and cancer.
KW - Combination therapies
KW - Thymosin α1
UR - http://www.scopus.com/inward/record.url?scp=35348982764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35348982764&partnerID=8YFLogxK
U2 - 10.1196/annals.1415.039
DO - 10.1196/annals.1415.039
M3 - Conference contribution
C2 - 17567941
AN - SCOPUS:35348982764
SN - 1573317012
SN - 9781573317016
VL - 1112
T3 - Annals of the New York Academy of Sciences
SP - 14
EP - 20
BT - Annals of the New York Academy of Sciences
ER -